
Plus Therapeutics, Inc. (NASDAQ:CNSY – Free Report) – Equities researchers at HC Wainwright issued their FY2026 earnings estimates for Plus Therapeutics in a research report issued to clients and investors on Wednesday, November 18th. HC Wainwright analyst S. Lee forecasts that the company will post earnings of ($4.63) per share for the year. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($4.40) per share. HC Wainwright also issued estimates for Plus Therapeutics’ Q4 2026 earnings at ($0.04) EPS, Q1 2027 earnings at ($0.50) EPS, Q2 2027 earnings at ($0.48) EPS, Q3 2027 earnings at ($0.46) EPS, Q4 2027 earnings at ($0.45) EPS, FY2027 earnings at ($1.90) EPS, FY2028 earnings at ($1.71) EPS, FY2029 earnings at ($0.97) EPS and FY2030 earnings at $0.33 EPS.
Other equities research analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Monday, November 2nd. Zacks Research raised Plus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, November 12th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Plus Therapeutics presently has an average rating of “Reduce”.
Get Our Latest Report on Plus Therapeutics
Plus Therapeutics Stock Down 1.0%
Shares of CNSY stock opened at $0.70 on Friday. Plus Therapeutics has a 12-month low of $0.43 and a 12-month high of $18.89. The stock has a 50 day moving average of $1.55. The stock has a market capitalization of $6.84 million, a PE ratio of -0.20 and a beta of 1.49.
Plus Therapeutics (NASDAQ:CNSY – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.16). The company had revenue of $0.72 million for the quarter. Plus Therapeutics had a negative net margin of 859.47% and a negative return on equity of 591.73%.
Trending Headlines about Plus Therapeutics
Here are a few of the latest headlines about CNSY:
- Positive Sentiment: HC Wainwright projects earnings improving over time, with annual losses narrowing from $4.63 per share in 2026 to $0.97 in 2029, followed by a forecast profit of $0.33 per share in 2030.
- Neutral Sentiment: The firm’s quarterly forecasts for 2027 indicate losses of $0.45–$0.50 per share. The reports update estimates but do not announce a change in the analyst’s rating or a new company development.
- Negative Sentiment: HC Wainwright’s 2026 loss estimate of $4.63 per share is worse than the cited consensus estimate of $4.40, underscoring ongoing earnings pressure.
About Plus Therapeutics
Plus Therapeutics is a clinical-stage biopharmaceutical company developing targeted radiotherapeutics for cancers of the central nervous system. The company is based in Austin, Texas, and was formerly known as Cytori Therapeutics. Its lead investigational product, REYOBIQ (rhenium-186 obisbemeda), is designed to deliver radiation directly to tumors in the brain and central nervous system. The treatment is being studied for conditions including recurrent glioblastoma and leptomeningeal metastases.
Recommended Stories
- Five stocks we like better than Plus Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
